$200m Series B ADC Biotech in search of CMO pre IPO

September 28, 2021

Pyxis Oncology are an exciting Boston based biotech working on antibody drug conjugates and monoclonal antibodies to treat a range of cancer indications. They had raised around $200m from top tier investors including RA Capital, Pfizer Ventures, Longwood Fund, Ipsen Ventures, Perceptive Advisors, BVF Partners and more. Approaching their IPO date with no CMO on…

Read More